Rohto Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Osaka Japan (1949)
Status: No NME R&D (1949)

Organization Overview

First Clinical Trial
2017
NCT03254758
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rohto Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

autologous mesenchymal stem cells (3 trials)

udi-001 (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 1)

Fibrosis (Phase 2)

Glomerulonephritis (Phase 1)

Glomerulonephritis, IGA (Phase 1)

Liver Cirrhosis (Phase 2)

Pneumonia (Phase 1)

Severe Acute Respiratory Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3